{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104104","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.712172+00:00","generated_at":"2026-05-15T13:33:28.026027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts","bullets":["Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.","Cash and equivalents $59.1M as of Dec 31, 2025.","PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.","Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.","R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104104","json":"https://secwatch.observer/filing/0001193125-26-104104.json","markdown":"https://secwatch.observer/filing/0001193125-26-104104.md","text":"https://secwatch.observer/filing/0001193125-26-104104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/0001193125-26-104104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/okur-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:33:28.026027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}